Doç. Dr. İsmail Mete Şaylan

ismailmete.saylan@surppirgic.com

• Üniversite: İstanbul Üniversitesi İstanbul Tıp Fakültesi 1996
• Uzmanlık: İstanbul Üniversitesi İstanbul Tıp Fakültesi Psikiyatri 2001
• Ulusal Sağlık Enstitüsü Beyin Araştırmaları Birimi Gönüllü
• Araştırmacı, Bethesda Amerika Birleşik Devletleri 2001
• Psikiyatrik Klinik Çalışmaların Bilimsel Yönü, Viyana Klinik
• Araştırmalar Okulu 2006
• Tıpta Sistematik Derleme, Oxford Üniversitesi İngiltere 2006
• Adler Koçluk Eğitimi 2017

• Türkiye Psikiyatri Derneği
• Alzheimer Vakfı
• Türkiye Sağlık Politikaları ve Ekonomisi Derneği
• TTB, İstanbul Tabipler Odası
• Uluslararası Farmakoekonomi ve Sonlanım Araştırmaları Derneği

• Şizofreni
• İkiuçlu Bozukluk (Bipolar Bozukluk)
• Obsesif Kompulsif Bozukluk
• Anksiyete Bozuklukları
• Depresif Bozukluklar, Tedaviye Dirençli Depresyon
• Tıbbi Durumlara Eşlik Eden Psikiyatrik Bozukluklar
• Duygudurum Bozuklukları
• Madde ve Alkol Bağımlılığı
• Kumar Bağımlılığı
• Elektrokonvüsif tedavi
• Transkranyal Manyetik Stimülasyon
• Elektrofizyoloji

1: Yazici O, Kora K, Uçok A, Saylan M, Ozdemir O, Kiziltan E, Ozpulat T. Unipolar mania: a distinct disorder? J Affect Disord. 2002 Sep;71(1-3):97-103. doi: 10.1016/s0165-0327(01)00416-5. PMID: 12167505.

2: Winterer G, Enoch MA, White KV, Saylan M, Coppola R, Goldman D. EEG phenotype in alcoholism: increased coherence in the depressive subtype. Acta Psychiatr Scand. 2003 Jul;108(1):51-60. doi: 10.1034/j.1600-0447.2003.00060.x. PMID: 12807377.

3: Yazici O, Kora K, Polat A, Saylan M. Controlled lithium discontinuation in bipolar patients with good response to long-term lithium prophylaxis. J Affect Disord. 2004 Jun;80(2-3):269-71. doi: 10.1016/S0165-0327(03)00133-2. PMID: 15207941.

4: Bilgic B, Baral-Kulaksizoglu I, Hanagasi H, Saylan M, Aykutlu E, Gurvit H, Emre M. Obsessive-compulsive disorder secondary to bilateral frontal damage due to a closed head injury. Cogn Behav Neurol. 2004 Jun;17(2):118-20. doi: 10.1097/01.wnn.0000117862.44205.ea. PMID: 15453521.

5: Uçok A, Tükel R, Ozgen G, Saylan M, Uzuner G. Fréquence des symptômes et du trouble obsessionnel compulsif chez les personnes atteintes de schizophrénie et leur importance pour le pronostic [Frequency of obsessive compulsive symptoms and disorder in patients with schizophrenia: importence for prognosis]. Encephale. 2006 Jan-Feb;32(1 Pt 1):41-4. French. doi: 10.1016/s0013-7006(06)76135-8. PMID: 16633289.

6: Saylan M, Khalaf I, Kadioglu A, Shoair KZ, Beheiry A, Wang WC, Kopernicky V, Esen A. Efficacy of tadalafil in Egyptian and Turkish men with erectile dysfunction. Int J Clin Pract. 2006 Jul;60(7):812-9. doi: 10.1111/j.1742-1241.2006.00993.x. PMID: 16846400; PMCID: PMC1569641.

7: Joy CB, Saylan M. Mother and baby units for schizophrenia. Cochrane Database Syst Rev. 2007 Jan 24;2007(1):CD006333. doi: 10.1002/14651858.CD006333. PMID: 17253587; PMCID: PMC11005945.

8: Dossenbach M, Treuer T, Kryzhanovskaya L, Saylan M, Dominguez S, Huang X; HGCQ, HGDQ, HGDT, and HGDV Study Team. Olanzapine versus chlorpromazine in the treatment of schizophrenia: a pooled analysis of four 6-week, randomized, open- label studies in the Middle East and North Africa. J Clin Psychopharmacol. 2007 Aug;27(4):329-37. doi: 10.1097/JCP.0b013e3180ca83b1. PMID: 17632215.

9: Treuer T, Oruc L, Loza N, El Saidi MA, Kovacs Z, Akkaya C, Gülseren S, Saylan M, Colman SA, Harrison GA. Acute phase results from STORM, a multicountry observational study of bipolar disorder treatment and outcomes. Psychiatr Danub. 2007 Dec;19(4):282-95. PMID: 18000479.

10: Kora K, Saylan M, Akkaya C, Karamustafalioglu N, Tomruk N, Yasan A, Oral T. Predictive factors for time to remission and recurrence in patients treated for acute mania: health outcomes of manic episodes (HOME) study. Prim Care Companion J Clin Psychiatry. 2008;10(2):114-9. doi: 10.4088/pcc.v10n0205. PMID: 18458722; PMCID: PMC2292434.

11: Treuer T, Martenyi F, Saylan M, Dyachkova Y. Factors associated with achieving minimally symptomatic status by patients with schizophrenia: results from the 3-year intercontinental schizophrenia outpatients health outcomes study. Int J Clin Pract. 2010 May;64(6):697-706. doi: 10.1111/j.1742-1241.2009.02331.x. Epub 2010 Mar 16. Erratum in: Int J Clin Pract. 2010 Sep;64(10):1459. PMID: 20345873. 

12: Saylan M, Treur MJ, Postema R, Dilbaz N, Savas H, Heeg BM, Drost PB. Cost- Effectiveness Analysis of Aripiprazole Augmentation Treatment of Patients with Major Depressive Disorder Compared to Olanzapine and Quetiapine Augmentation in Turkey: A Microsimulation Approach. Value Health Reg Issues. 2013 Sep- Oct;2(2):171-180. doi: 10.1016/j.vhri.2013.06.004. Epub 2013 Aug 3. PMID: 29702862.

13: Safak YE, Kockaya G, Yenilmez FB, Saylan M, Tatar M, Hilal VE, Vural IM, Akbulat A, Gursoz H, Artiran G, Kerman S. Impact of Health Policy Changes on Trends of Pharmaceutical Market in Turkey. Value Health. 2014 Nov;17(7):A408. doi: 10.1016/j.jval.2014.08.957. Epub 2014 Oct 26. PMID: 27200995.

14: Kockaya G, Yenilmez FB, Saylan M, Safak YE, Tatar M, Hilal VE, Vural IM, Akbulat A, Gursoz H, Artiran G, Kerman S. Impact of Health Policy Changes on the Growth Locally Manufactured and Imported Pharmaceutical Markets of Top Selling Atc1 Phramaceutical Group (Alimentary and Metabolism (A0) In Turkey. Value Health. 2014 Nov;17(7):A410-1. doi: 10.1016/j.jval.2014.08.969. Epub 2014 Oct 26. PMID: 27201004.

15: Hilal VE, Kockaya G, Yenilmez FB, Saylan M, Safak YE, Tatar M, Vural IM, Akbulat A, Gursoz H, Artiran G, Kerman S. Impact of Health Policy Changes on the Growth Locally Manufactured and Imported Pharmaceutical Markets In Turkey. Value Health. 2014 Nov;17(7):A410. doi: 10.1016/j.jval.2014.08.967. Epub 2014 Oct 26. PMID: 27201006.

16: Yenilmez FB, Kockaya G, Saylan M, Safak YE, Tatar M, Hilal VE, Vural IM, Akbulat A, Gursoz H, Artiran G, Kerman S. Impact of Health Policy Changes on the Cost Sales of 5 Top Selling ATC1 Phramaceutical Groups in Turkey. Value Health. 2014 Nov;17(7):A410. doi: 10.1016/j.jval.2014.08.964. Epub 2014 Oct 26. PMID: 27201009.

17: Saylan M, Safak YE, Yenilmez FB, Kockaya G, Tatar M, Hilal VE, Vural IM, Akbulat A, Gursoz H, Artiran G, Kerman S. Impact Of Health Policy Changes on Unit Sales of 5 Top Selling Atc1 Phramaceutical Groups In Turkey. Value Health. 2014 Nov;17(7):A411. doi: 10.1016/j.jval.2014.08.972. Epub 2014 Oct 26. PMID: 27201012.

18: Beykoz V, Saylan M. Applicability of Turkish Pricing Policy on Price Increases. Value Health. 2014 Nov;17(7):A411. doi: 10.1016/j.jval.2014.08.973. Epub 2014 Oct 26. PMID: 27201013.

19: Saylan M, Beykoz V, Keskinaslan A. Clinical Trial-Based Cost-Effectiveness Analysis of Indacaterol (ONBREZ® 150 MCG) Versus Tiotropium (SPIRIVA®) in the Treatment of Chronic Obstructive Pulmonary Disease (COPD) IN TURKEY. Value Health. 2014 Nov;17(7):A588. doi: 10.1016/j.jval.2014.08.2011. Epub 2014 Oct 26. PMID: 27202003. 

20: Tatar M, Sezen S, Senturk A, Balp MM, Saylan M, Keskinaslan A. Cost- Effectiveness of Omalizumab in Chronic Idiopathic Urticaria Refractory to H1-Antihistamines in Turkey. Value Health. 2014 Nov;17(7):A604. doi: 10.1016/j.jval.2014.08.2101. Epub 2014 Oct 26. PMID: 27202092.

21: Tatar M, Senturk A, Ergin G, Tuna E, Mat C, Bulbul BE, Artuz F, Gurer MA, Atakan N, Inaloz S, Sezen S, Keskinaslan A, Saylan M. Cost-Analysis of Chronic Idiopathic Urticaria Disease. Value Health. 2014 Nov;17(7):A606. doi: 10.1016/j.jval.2014.08.2114. Epub 2014 Oct 26. PMID: 27202104.

22: Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015 Aug 22;386(9995):743-800. doi: 10.1016/S0140-6736(15)60692-4. Epub 2015 Jun 7. PMID: 26063472; PMCID: PMC4561509.

23: Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015 Dec 5;386(10010):2287-323. doi: 10.1016/S0140-6736(15)00128-2. Epub 2015 Sep 11. PMID: 26364544; PMCID: PMC4685753.

24:  The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016 Sep 10;388(10049):1081-1088. doi: 10.1016/S0140-6736(16)30579-7. Epub 2016 Jul 7. PMID: 27394647; PMCID: PMC5100695.

25: Aras D, Aydoğdu S, Bozkurt E, Çavuşoğlu Y, Eren M, Erol Ç, Güleç S, Kızılırmak P, Öngen Z, Özdemir O, Saylan M, Tokgözoğlu L, Yeter E, Yılmaz MB. Cost of heart failure management in Turkey: results of a Delphi Panel. Anatol J Cardiol. 2016 Aug;16(8):554-62. doi: 10.14744/AnatolJCardiol.2016.6999. PMID 27515102; PMCID: PMC5368510.

26: GBD 2015 Maternal Mortality Collaborators. Global, regional, and national levels of maternal mortality, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016 Oct 8;388(10053):1775-1812. doi: 10.1016/S0140-6736(16)31470-2. Erratum in: Lancet. 2017 Jan 7;389(10064):e1. doi: 10.1016/S0140-6736(16)32609-5. PMID: 27733286; PMCID: PMC5224694. 

27: Yılmaz ES, Koçkaya G, Yenilmez FB, Saylan M, Tatar M, Akbulat A, Gürsöz H, Kerman S. Impact of Health Policy Changes on Trends in the Pharmaceutical Market in Turkey. Value Health Reg Issues. 2016 Sep;10:48-52. doi: 10.1016/j.vhri.2016.07.002. Epub 2016 Sep 2. PMID: 27881277.

28: GBD 2015 Tobacco Collaborators. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990-2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet. 2017 May 13;389(10082):1885-1906. doi: 10.1016/S0140-6736(17)30819-X. Epub 2017 Apr 5. Erratum in: Lancet. 2017 Oct 7;390(10103):1644. doi: 10.1016/S0140-6736(17)32559-X. PMID: 28390697; PMCID: PMC5439023.

29: GBD 2015 Healthcare Access and Quality Collaborators. Electronic address: cjlm@uw.edu; GBD 2015 Healthcare Access and Quality Collaborators. Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet. 2017 Jul 15;390(10091):231-266. doi: 10.1016/S0140-6736(17)30818-8. Epub 2017 May 18. PMID: 28528753; PMCID: PMC5528124.

30: GBD 2015 Eastern Mediterranean Region Mental Health Collaborators. The burden of mental disorders in the Eastern Mediterranean region, 1990-2015: findings from the global burden of disease 2015 study. Int J Public Health. 2018 May;63(Suppl 1):25-37. doi: 10.1007/s00038-017-1006-1. Epub 2017 Aug 3. PMID: 28776247; PMCID: PMC5973970.

31: GBD 2015 Eastern Mediterranean Region Maternal Mortality Collaborators. Maternal mortality and morbidity burden in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study. Int J Public Health. 2018 May;63(Suppl 1):47-61. doi: 10.1007/s00038-017-1004-3. Epub 2017 Aug 3. PMID: 28776252; PMCID: PMC5973988.

32: GBD 2016 SDG Collaborators. Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. Lancet. 2017 Sep 16;390(10100):1423-1459. doi: 10.1016/S0140-6736(17)32336-X. Epub 2017 Sep 12. Erratum in: Lancet. 2017 Sep 30;390(10102):e23. doi: 10.1016/S0140-6736(17)32441-8. Erratum in: Lancet. 2017 Oct 28;390(10106):e38. doi: 10.1016/S0140-6736(17)32650-8. PMID: 28916366; PMCID: PMC5603800.

33: GBD 2016 Mortality Collaborators. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017 Sep 16;390(10100):1084-1150. doi: 10.1016/S0140-6736(17)31833-0. Erratum in: Lancet. 2017 Oct 28;390(10106):e38. doi: 10.1016/S0140-6736(17)32645-4. PMID: 28919115; PMCID: PMC5605514. 

34: GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017 Nov;16(11):877-897. doi: 10.1016/S1474-4422(17)30299-5. Epub 2017 Sep 17. PMID: 28931491; PMCID: PMC5641502.

35: GBD 2016 Healthcare Access and Quality Collaborators. Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet. 2018 Jun 2;391(10136):2236-2271. doi: 10.1016/S0140-6736(18)30994-2. Epub 2018 Jun 1. PMID: 29893224; PMCID: PMC5986687.

36: GBD 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2018 Sep 22;392(10152):1015-1035. doi: 10.1016/S0140-6736(18)31310-2. Epub 2018 Aug 23. Erratum in: Lancet. 2018 Sep 29;392(10153):1116. doi: 10.1016/S0140-6736(18)32338-9. Erratum in: Lancet. 2019 Jun 22;393(10190):e44. doi: 10.1016/S0140-6736(19)31050-5. PMID: 30146330; PMCID: PMC6148333.

37: GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1789-1858. doi: 10.1016/S0140-6736(18)32279-7. Epub 2018 Nov 8. Erratum in: Lancet. 2019 Jun 22;393(10190):e44. doi: 10.1016/S0140-6736(19)31047-5. PMID: 30496104; PMCID: PMC6227754.

38: GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1923-1994. doi: 10.1016/S0140-6736(18)32225-6. Epub 2018 Nov 8. Erratum in: Lancet. 2019 Jan 12;393(10167):132. doi: 10.1016/S0140-6736(18)33216-1. Erratum in: Lancet. 2019 Jun 22;393(10190):e44. doi: 10.1016/S0140-6736(19)31429-1. PMID: 30496105; PMCID: PMC6227755.

39: GBD 2017 SDG Collaborators. Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):2091-2138. doi: 10.1016/S0140-6736(18)32281-5. Epub 2018 Nov 8. Erratum in: Lancet. 2019 Jun 22;393(10190):e44. doi: 10.1016/S0140-6736(19)31048-7. PMID: 30496107; PMCID: PMC6227911.

40: GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 Jan;18(1):88-106. doi: 10.1016/S1474-4422(18)30403-4. Epub 2018 Nov 26. PMID: 30497964; PMCID: PMC6291454.

41: Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017. Inj Prev. 2020 Oct;26(Supp 1):i12-i26. doi: 10.1136/injuryprev-2019-043296. Epub 2020 Jan 8. Erratum in: Inj Prev. 2020 Oct;26(Supp 1):i164. doi: 10.1136/injuryprev-2019-043296corr1. PMID: 31915273; PMCID: PMC7571356.

42: GBD 2019 Demographics Collaborators. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1160-1203. doi: 10.1016/S0140-6736(20)30977-6. PMID: 33069325; PMCID: PMC7566045.

43: GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021 Feb;9(2):e144-e160. doi: 10.1016/S2214-109X(20)30489-7. Epub 2020 Dec 1. Erratum in: Lancet Glob Health. 2021 Apr;9(4):e408. doi: 10.1016/S2214-109X(21)00050-4. PMID: 33275949; PMCID: PMC7820391.

44.Global Burden of Cardiovascular Diseases Writing Group. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021. doi: 10.1016/j.jacc.2020.11.010. Erratum in: J Am Coll Cardiol. 2021 Apr 20;77(15):1958-1959. doi: 10.1016/j.jacc.2021.02.039. PMID: 33309175; PMCID: PMC7755038.

45: Koçkaya G, Atalay S, Oğuzhan G, Kurnaz M, Ökçün S, Sar Gedik Ç, Şaylan M, Şencan N. Analysis of patient access to orphan drugs in Turkey. Orphanet J Rare Dis. 2021 Feb 6;16(1):68. doi: 10.1186/s13023-021-01718-3. PMID: 33549137; PMCID: PMC7868010.

46: GBD 2019 Tobacco Collaborators. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet. 2021 Jun 19;397(10292):2337-2360. doi: 10.1016/S0140-6736(21)01169-7. Epub 2021 May 27. Erratum in: Lancet. 2021 Jun 19;397(10292):2336. doi: 10.1016/S0140-6736(21)01282-4. PMID: 34051883; PMCID: PMC8223261.

47: GBD 2019 Dementia Collaborators. The Burden of Dementia due to Down Syndrome, Parkinson's Disease, Stroke, and Traumatic Brain Injury: A Systematic Analysis for the Global Burden of Disease Study 2019. Neuroepidemiology. 2021;55(4):286-296. doi: 10.1159/000515393. Epub 2021 Jun 28. PMID: 34182555; PMCID: PMC8794050.

48: GBD 2019 Collaborators. Global mortality from dementia: Application of a new method and results from the Global Burden of Disease Study 2019. Alzheimers Dement (N Y). 2021 Jul 27;7(1):e12200. doi: 10.1002/trc2.12200. PMID: 34337138; PMCID: PMC8315276.

49: GBD 2019 Dementia Collaborators. Use of multidimensional item response theory methods for dementia prevalence prediction: an example using the Health and Retirement Survey and the Aging, Demographics, and Memory Study. BMC Med Inform Decis Mak. 2021 Aug 11;21(1):241. doi: 10.1186/s12911-021-01590-y. PMID: 34380485; PMCID: PMC8356410.

50: GBD 2019 Under-5 Mortality Collaborators. Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019. Lancet. 2021 Sep 4;398(10303):870-905. doi: 10.1016/S0140-6736(21)01207-1. Epub 2021 Aug 17. PMID: 34416195; PMCID: PMC8429803.

51: GBD 2019 Adolescent Young Adult Cancer Collaborators. The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Oncol. 2022 Jan;23(1):27-52. doi: 10.1016/S1470-2045(21)00581-7. Epub 2021 Dec 3. PMID: 34871551; PMCID: PMC8716339.

52: Global Burden of Disease 2019 Cancer Collaboration; Kocarnik JM, ve ark.  Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019. JAMA Oncol. 2022 Mar 1;8(3):420-444. doi: 10.1001/jamaoncol.2021.6987. PMID: 34967848; PMCID: PMC8719276.

53: GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022 Feb;7(2):e105-e125. doi: 10.1016/S2468-2667(21)00249-8. Epub 2022 Jan 6. PMID: 34998485; PMCID: PMC8810394.

54. How Useful Are Digital Health Terms for Outcomes Research? An ISPOR Special Interest Group Report. Value Health. 2022 Sep;25(9):1469-1479. doi: 10.1016/j.jval.2022.04.1730. PMID: 36049797. 

55: GBD 2021 Demographics Collaborators. Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. Lancet. 2024 May 18;403(10440):1989-2056. doi: 10.1016/S0140-6736(24)00476-8. Epub 2024 Mar 11. PMID: 38484753; PMCID: PMC11126395.

56: GBD 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024 Apr;23(4):344-381. doi: 10.1016/S1474-4422(24)00038-3. Epub 2024 Mar 14. Erratum in: Lancet Neurol. 2024 May;23(5):e9. doi: 10.1016/S1474-4422(24)00114-5. Erratum in: Lancet Neurol. 2024 Jul;23(7):e11. doi: 10.1016/S1474-4422(24)00231-X. PMID: 38493795; PMCID: PMC10949203.

57: GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024 May 18;403(10440):2100-2132. doi: 10.1016/S0140-6736(24)00367-2. Epub 2024 Apr 3. Erratum in: Lancet. 2024 May 18;403(10440):1988. doi: 10.1016/S0140-6736(24)00824-9. PMID: 38582094; PMCID: PMC11126520.

58: GBD 2019 North Africa and the Middle East Neurology Collaborators. The burden of neurological conditions in north Africa and the Middle East, 1990-2019: a systematic analysis of the Global Burden of Disease Study 2019. Lancet Glob Health. 2024 Jun;12(6):e960-e982. doi:10.1016/S2214-109X(24)00093-7. Epub 2024 Apr 8. PMID: 38604203; PMCID: PMC11099299.

59: Vision Loss Expert Group of the Global Burden of Disease Study; GBD 2019 Blindness and Vision Impairment Collaborators. Global estimates on the number of people blind or visually impaired by age-related macular degeneration: a meta- analysis from 2000 to 2020. Eye (Lond). 2024 Aug;38(11):2070-2082. doi: 10.1038/s41433-024-03050-z. Epub 2024 Jul 4. PMID: 38965321; PMCID: PMC11269688.

60: Vision Loss Expert Group of the Global Burden of Disease Study; GBD 2019 Blindness and Vision Impairment Collaborators. Global estimates on the number of people blind or visually impaired by Uncorrected Refractive Error: a meta- analysis from 2000 to 2020. Eye (Lond). 2024 Aug;38(11):2083-2101. doi: 10.1038/s41433-024-03106-0. Epub 2024 Jul 4. PMID: 38965322; PMCID: PMC11269735.

61: GBD 2021 Tobacco Forecasting Collaborators. Forecasting the effects of smoking prevalence scenarios on years of life lost and life expectancy from 2022 to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Public Health. 2024 Oct;9(10):e729-e744. doi: 10.1016/S2468-2667(24)00166-X. PMID: 39366729; PMCID: PMC11447278.

62: GBD 2021 Global Stillbirths Collaborators. Global, regional, and national stillbirths at 20 weeks' gestation or longer in 204 countries and territories, 1990-2021: findings from the Global Burden of Disease Study 2021. Lancet. 2024 Nov 16;404(10466):1955-1988. doi: 10.1016/S0140-6736(24)01925-1. Epub 2024 Nov 4. PMID: 39510107; PMCID: PMC11694012.